Skip to main content

Excessive Daytime Sleepiness

1
Pipeline Programs
4
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Biocorp
BiocorpFrance - Issoire
1 program
1
BEN-2001Phase 21 trial
Active Trials
NCT03194217Completed244Est. May 2019
Teva
TevaIsrael - Petach Tikva
2 programs
ArmodafinilPHASE_31 trial
Armodafinil 100 to 250 mg/dayPHASE_31 trial
Active Trials
NCT00228566Completed247Est. Jul 2006
NCT00228553Completed743Est. Jul 2006
Centessa Pharmaceuticals
1 program
ORX142 TabletsPHASE_11 trial
Active Trials
NCT07082829Recruiting208Est. Jun 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
TevaArmodafinil
TevaArmodafinil 100 to 250 mg/day
BiocorpBEN-2001
Centessa PharmaceuticalsORX142 Tablets

Clinical Trials (4)

Total enrollment: 1,442 patients across 4 trials

NCT00228566TevaArmodafinil

Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome

Start: Oct 2005Est. completion: Jul 2006247 patients
Phase 3Completed
NCT00228553TevaArmodafinil 100 to 250 mg/day

Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness

Start: May 2004Est. completion: Jul 2006743 patients
Phase 3Completed

BEN-2001 in Parkinson Disease Patients With Excessive Daytime Sleepiness

Start: Nov 2017Est. completion: May 2019244 patients
Phase 2Completed

A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of Age

Start: Jun 2025Est. completion: Jun 2026208 patients
Phase 1Recruiting

Related Jobs

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 1,442 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.